MARKET

CORT

CORT

Corcept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.77
-0.18
-0.76%
After Hours: 22.30 -0.47 -2.04% 17:15 04/16 EDT
OPEN
23.13
PREV CLOSE
22.94
HIGH
23.16
LOW
22.43
VOLUME
412.99K
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
11.57
MARKET CAP
2.67B
P/E (TTM)
26.64
1D
5D
1M
3M
1Y
5Y
Global Pituitary ACTH Hypersecretion Drug Market Growth, Status and Outlook Research Report 2021
Apr 12, 2021 (Heraldkeepers) -- Research ScopeThis report researches the worldwide Pituitary ACTH Hypersecretion Drug market size (value) in key regions like...
Heraldkeepers · 5d ago
Corcept lower after NASH trial shows ‘suspended’ in federal register
Corcept Therapeutics ([[CORT]] -1.1%) is trading lower after an update on federal register for clinical trials indicates ‘suspended’ as recruitment status for a Phase 2 clinical trial evaluating Miricorilant in patients with
Seekingalpha · 04/08 19:06
Imagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 398% Higher
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well...
Simply Wall St. · 04/05 07:42
Corcept Therapeutics Stock Gives Every Indication Of Being Modestly Overvalued
GuruFocus News · 03/30 23:58
Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?
Zacks.com · 03/25 19:42
Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant
Zacks.com · 03/16 18:54
Best Health Care Website to be Named by Web Marketing Association in 25th Annual WebAward Competition
Mar 16, 2021 (PR.com via COMTEX) -- Boston, MA, March 16, 2021 --(PR.com)-- The Web Marketing Association is looking for the best healthcare websites in the...
PR.com · 03/16 13:35
Corcept starts enrollment in early-stage relacorilant-keytruda adrenal cancer study
Corcept Therapeutics (CORT) announces enrollment of the first patient in the Phase 1b trial of relacorilant in combination with Merck's blockbuster cancer drug Keytruda in certain patients with adrenal cancer.The open-label, Phase
Seekingalpha · 03/15 11:46
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CORT. Analyze the recent business situations of Corcept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CORT stock price target is 27.00 with a high estimate of 35.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 329
Institutional Holdings: 104.14M
% Owned: 88.77%
Shares Outstanding: 117.31M
TypeInstitutionsShares
Increased
62
2.37M
New
36
2.37M
Decreased
93
6.82M
Sold Out
31
2.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.98%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Director/Independent Director
James Wilson
President/Chief Executive Officer/Director
Joseph Belanoff
Chief Financial Officer
Atabak Mokari
Senior Vice President
Sean Maduck
Independent Director
G. Leonard Baker
Chief Accounting Officer
J.D. Lyon
Independent Director
G.Leonard Baker
Other
Andreas Grauer
Secretary
Gary Robb
Director
Gillian Cannon
Independent Director
Gregg Alton
Independent Director
George Baker
Independent Director
David Mahoney
Independent Director
Kimberly Park
Independent Director
Daniel Swisher
No Data
About CORT
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Webull offers kinds of Corcept Therapeutics Incorporated stock information, including NASDAQ:CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.